- Home
- RVI vs VOR Comparison
RVI vs VOR Comparison
Compare RVI & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVI | VOR |
|---|---|---|
| Founded | N/A | 2015 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.4M | 813.3M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RVI | VOR |
|---|---|---|
| Price | $35.77 | $14.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $45.33 |
| AVG Volume (30 Days) | ★ 816.1K | 742.5K |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.21 | $0.18 |
| 52 Week High | $77.39 | $49.95 |
Technical Indicators
Market Signals| Indicator | RVI | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 50.19 |
| Support Level | $24.27 | $13.73 |
| Resistance Level | $63.18 | $14.73 |
| Average True Range (ATR) | 4.50 | 0.95 |
| MACD | -2.29 | -0.02 |
| Stochastic Oscillator | 5.27 | 59.80 |
Price Performance
Historical ComparisonAbout RVI Robinhood Ventures Fund I Common Shares of Beneficial Interest
Robinhood Ventures Fund I is a closed-end investment company. The investment objective, the Fund will mainly invest, under normal circumstances, in a concentrated portfolio generally consisting of ten or more private companies that, in the view, are growing companies at the frontiers of their respective sectors and industries. The Fund operates as a single segment.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.